Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18476744 | 1.00 | PTPN1 (0.36) | PTPN1ALDH1A1MEN1KMT2ASYK | |
| SCHEMBL18470440 | 0.92 | SYK (0.34) | SYK | |
| SCHEMBL16998966 | 0.92 | SYK (0.34) | SYK | |
| SCHEMBL18237197 | 0.89 | PTPN1 (0.41) | PTPN1ALDH1A1MEN1KMT2AP2RX7 | |
| SCHEMBL27047943 | 0.86 | PTPN1 (0.36) | PTPN1ALDH1A1KMT2ASYKP2RX7 | |
| SCHEMBL16989068 | 0.82 | PTPN1 (0.34) | PTPN1ALDH1A1MEN1KMT2AP2RX7 | |
| SCHEMBL20244143 | 0.82 | PTPN1 (0.34) | PTPN1ALDH1A1MEN1KMT2AP2RX7 | |
| SCHEMBL13302748 | 0.82 | SYK (0.36) | SYK | |
| SCHEMBL3335928 | 0.82 | SYK (0.36) | SYK | |
| SCHEMBL3338219 | 0.80 | SYK (0.35) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12084414-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3102200-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220281813-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-9499532-B2 | Therapeutic compounds and compositions | eXIthera Pharmaceuticals Inc. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | US | disclosed |
| WO-2015120062-A2 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | PTPN1 4272/4885ALDH1A1 4490/4885MEN1 261/4885 |
| US-12084414-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | PTPN1 4272/4885ALDH1A1 4490/4885MEN1 261/4885 |
| US-20220281813-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | PTPN1 4272/4885ALDH1A1 4490/4885MEN1 261/4885 |
| US-10259785-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | PTPN1 4272/4885ALDH1A1 4490/4885MEN1 261/4885 |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | PTPN1 4272/4885ALDH1A1 4490/4885MEN1 261/4885 |
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | PTPN1 4272/4885ALDH1A1 4490/4885MEN1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.